UNIVERSITY OF MICHIGAN
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1817-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.umich.edu
Clinical Trials
1.4k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1185 trials with phase data)• Click on a phase to view related trials
Usability of the MeTime MS App
- Conditions
- Multiple SclerosisPainFatigue Symptom
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 10
- Registration Number
- NCT07123272
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Evaluating a Wearable Tracking System for Family Caregivers of Persons With Dementia With Wandering Concerns
- Conditions
- DementiaCaregiverMemory Loss
- First Posted Date
- 2025-08-11
- Last Posted Date
- 2025-08-11
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 140
- Registration Number
- NCT07116122
- Locations
- 🇺🇸
University of Michigan Transportation Research Institute, Ann Arbor, Michigan, United States
Population Based Strategies for Standardized Surgical Care
- Conditions
- Hernia, Abdominal
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-08-06
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 68
- Registration Number
- NCT07106541
- Locations
- 🇺🇸
University of Michigan and other Michigan Surgical Quality Collaborative sites, Ann Arbor, Michigan, United States
Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain
- Conditions
- EndometriosisPelvic Pain
- Interventions
- Drug: Relugolix CT
- First Posted Date
- 2025-08-03
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 130
- Registration Number
- NCT07100782
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Neurobehavioral Signatures of Sign- and Goal-Tracking in Emerging Adults: Translation of a Preclinical Model
- Conditions
- Substance UseHealthy
- First Posted Date
- 2025-07-30
- Last Posted Date
- 2025-07-30
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 294
- Registration Number
- NCT07094061
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 283
- Next
News
University of Michigan Develops At-Home Melanoma Detection Patch Using Microneedle Technology
Researchers at the University of Michigan have developed the ExoPatch, a silicone patch with star-shaped microneedles that can detect melanoma by capturing disease-specific exosomes from skin tissue.
Biomerica Appoints Scott Madel as Chief Commercial Officer to Drive inFoods IBS Test Commercialization
Biomerica has appointed Scott Madel as Chief Commercial Officer to accelerate commercialization of its inFoods IBS diagnostic test, bringing over 20 years of experience in laboratory testing and clinical diagnostics.
Courage Therapeutics Appoints Giovanni Ferrara as CEO to Advance Melanocortin-Targeted Obesity Treatments
Courage Therapeutics has appointed biopharma veteran Giovanni Ferrara as CEO following a significant investment from Arsenal Bridge Ventures in May.
Epcoritamab Demonstrates Durable 3-Year Remissions in Relapsed/Refractory Large B-Cell Lymphoma
Epcoritamab-bysp achieved durable complete responses in patients with relapsed/refractory large B-cell lymphoma, with 96% of complete responders at 2 years maintaining remission at 3 years.
Mayo Clinic Researchers Discover Drug Treatment to Triple Donor Heart Preservation Time
Mayo Clinic researchers identified that mineralocorticoid receptor proteins clump together during cold storage, causing cardiac damage through increased inflammation and cell death.
DT-109: Novel Glycine-Based Compound Shows Dual Efficacy Against Atherosclerosis and MASH
• University of Michigan researchers have demonstrated that DT-109, a glycine-based tripeptide, significantly reduces atherosclerotic plaque formation in nonhuman primates while inhibiting vascular calcification processes. • The compound, which previously showed efficacy in treating metabolic dysfunction-associated steatotic liver disease (MASH), represents a potential breakthrough as a dual-action therapy addressing both liver dysfunction and cardiovascular complications. • Unlike conventional treatments that primarily lower cholesterol, DT-109 targets underlying inflammatory pathways including NLRP3 inflammasome signaling, potentially addressing root causes of atherosclerosis rather than just managing symptoms.
Breakthrough T1D Invests $2.8 Million to Establish Joint Cardiorenal Center of Excellence for Type 1 Diabetes Research
Breakthrough T1D has awarded $2.8 million over three years to create the U-M-OHSU Cardiorenal Center of Excellence, expanding research on heart and kidney complications in type 1 diabetes patients.
Trump Administration Cancels $800 Million in LGBTQ Health Research Funding
The Trump administration has terminated 323 NIH grants worth $806 million focused on LGBTQ health research, affecting studies on HIV prevention, cancer, and mental health.
Loneliness Epidemic Shifts: Middle-Aged Americans More Isolated Than Seniors, New Research Reveals
One-third of Americans aged 50-80 report feeling lonely, with rates returning to pre-pandemic levels after peaking at 42% during COVID-19, according to University of Michigan research.
Teen Substance Use Remains at Historic Lows in 2024, NIH Survey Reveals
Substance use among adolescents has maintained historically low levels for the fourth consecutive year following significant declines during the COVID-19 pandemic, according to the latest NIH-funded Monitoring the Future survey.